en · de · es · fr · pt
dihexa-notes.peptides6088.com › Data › Chemical Identity And Naming — Evidence Review

Chemical Identity And Naming — Evidence Review

By Editorial Desk · published 2026-01-11 · last reviewed 2026-02-19 · Data

Everything below concerns stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-02-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Chemical Identity and Naming

Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.

The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.

Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.

Handling, Storage, and Verification

Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.

Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.

Dihexa at a glance

PropertyValueNotes
Chemical classSynthetic peptide analogModeled on angiotensin IV; not a natural hormone.
Common synonymsDihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amideNaming conventions differ across vendors and papers.
CAS Registry Number1401708-83-6Listed in some chemical databases; verify against primary sources.
AppearanceWhite to off-white powderTypical form for lyophilized research peptides.
SolubilitySoluble in DMSO; limited in waterOrganic stock solutions are common in laboratory settings.

Preclinical Research and Regulation

Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.

Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.

Related pages on this site

Identity And Regulatory Status

Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.

Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.

Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.

Handling and Quality Verification

In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.

Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.

Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.

Reference notes

=== Membrane spanning === α-Helices are also the most common protein structure element that crosses biological membranes (transmembrane protein), presumably because the helical structure can satisfy all backbone hydrogen-bonds internally, leaving no polar groups exposed to the membrane if the sidechains are hydrophobic. Proteins are sometimes anchored by a single membrane-spanning helix, sometimes by a pair, and sometimes by a helix bundle, most classically consisting of seven helices arranged up-and-down in a ring such as for rhodopsins (see image at right) and other G protein–coupled receptors (GPCRs). The structural stability between pairs of α-Helical transmembrane domains rely on conserved membrane interhelical packing motifs, for example, the Glycine-xxx-Glycine (or small-xxx-small) motif.

The science behind food and food production involves studying how food behaves and how it can be improved. Researchers analyze longevity and composition (i.e., ingredients, vitamins, minerals, etc.) of foods, as well as how to ensure food safety.

== Peace == The Global Peace Index 2018, published by the Institute for Economics and Peace ranked Thailand 113 of 163 nations for overall level of peacefulness (1=most peaceful; 163=least peaceful). Other ASEAN nations ranked were: Singapore, 8; Malaysia, 25; Laos, 46; Indonesia, 55; Vietnam, 60; Cambodia, 96; Myanmar, 122; and Philippines, 137.

Sources: en.wikipedia.org

Reference notes

Xanomeline (developmental code name LY-246,708) is a small molecule muscarinic acetylcholine receptor agonist that was synthesized in a collaboration between Eli Lilly and Novo Nordisk as an investigational therapeutic being studied for the treatment of central nervous system (CNS) disorders. Its pharmacological action is mediated primarily through stimulation of central nervous system muscarinic M1 and M4 receptor subtypes. Xanomeline is a non-selective muscarinic acetylcholine receptor agonist with similar high affinity for all five muscarinic acetylcholine receptor subtypes but has greater agonistic activity at the M1 and M4 subtypes. Xanomeline/trospium (Cobenfy), is a combination medication used in the treatment of schizophrenia.

On April 25, 2023, Musk announced that posts by verified accounts would now be prioritized ahead of unverified users, but behind those of the user's own follows, in replies to tweets. On April 30, 2023, multiple legacy verified users began noticing a bug that temporarily restored the legacy blue checkmark by changing their bio. On October 17, 2023, X announced that it would trial a scheme requiring new users who register via the website in New Zealand and the Philippines to pay US$1 per-year in order to use the platform. If the user does not subscribe, they will only receive read-only access to the platform. It was stated that this system was required to "bolster our already significant efforts to reduce spam, manipulation of our platform and bot activity."

Layne Staley – lead and backing vocals, rhythm guitar on "Hate to Feel" and "Angry Chair"; sun logo/icons Jerry Cantrell – guitars, backing vocals, co-lead vocals on "Down in a Hole" and "Would?" Mike Starr – bass Sean Kinney – drums Additional personnel

== Clinical significance == Patients with salt-sensitive hypertension have higher plasma ET-1. Endothelin-1 receptor antagonists (Bosentan) are used in the treatment of pulmonary hypertension. Use of these antagonists prevents pulmonary arterial constriction and thus inhibits pulmonary hypertension. As of 2020, the role of endothelin-1 in affecting lipid metabolism and insulin resistance in obesity mechanisms was under clinical research.

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.

Is dihexa the same as angiotensin IV?

No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.

How is dihexa named in chemical databases?

It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.

How is dihexa usually stored?

The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.

Network